

2019 Regular Session

HOUSE BILL NO. 169

BY REPRESENTATIVE HOFFMANN AND SENATOR THOMPSON

1 AN ACT

2 To amend and reenact R.S. 44:4.1(B)(26) and to enact R.S. 40:1046(A)(6), Subpart D of
3 Part III of Subchapter A of Chapter 5-D of Title 40 of the Louisiana Revised Statutes
4 of 1950, to be comprised of R.S. 40:1168.1 through 1168.6, and R.S. 40:1046(A)(6)
5 of Section 2 of Act No. 96 of the 2016 Regular Session of the Legislature of
6 Louisiana, relative to information concerning health effects, events, and outcomes
7 associated with patient use of medical marijuana; to authorize the Louisiana State
8 Board of Medical Examiners to establish and maintain an electronic data system for
9 the collection of such information; to require that the board collaborate with certain
10 institutions in the design of the data system; to provide specifications for components
11 of the data system; to provide for reporting of data into the system; to restrict
12 disclosure and uses of data from the system; to provide for a public records
13 exception; to provide legislative findings and definitions; to authorize administrative
14 rulemaking; and to provide for related matters.

15 Be it enacted by the Legislature of Louisiana:

16 Section 1. R.S. 40:1046(A)(6) and Subpart D of Part III of Subchapter A of Chapter
17 5-D of Title 40 of the Louisiana Revised Statutes of 1950, comprised of R.S. 40:1168.1
18 through 1168.6, are hereby enacted to read as follows:

19 §1046. Recommendation of marijuana for therapeutic use; rules and regulations;
20 Louisiana Board of Pharmacy and the adoption of rules and regulations
21 relating to the dispensing of recommended marijuana for therapeutic use; the
22 Department of Agriculture and Forestry and the licensure of a production
23 facility

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

A.

* * *

(6) Physicians shall report adverse events and health outcomes associated with a patient's use of medical marijuana to the data system provided for in R.S. 40:1168.1 et seq.

* * *

SUBPART D. MEDICAL MARIJUANA:
HEALTH INFORMATION DATA SYSTEM

§1168.1. Findings and purpose

A. The legislature hereby finds and declares that, while specific definitions of the term vary, "evidence-based medicine" refers to the practice of medicine based upon evidence derived from research and in a manner in which the physician bases clinical decisions upon such evidence.

B. The purpose of this Subpart is to promote the practice of evidence-based medicine in Louisiana through the creation of a system which facilitates the collection and analysis of information on health effects, events, and outcomes associated with the use of medical marijuana by patients in this state.

§1168.2. Definitions

For purposes of this Subpart, the following terms have the meaning ascribed to them in this Section:

(1) "Adverse event" means any incident relating to the use of a drug prescribed or recommended to a patient that may result in serious harm or injury to the patient or in the patient's death.

(2) "Board" means the Louisiana State Board of Medical Examiners.

(3) "Data system" means the system authorized and provided for in R.S. 40:1168.3.

(4) "Medical marijuana" means the therapeutic substance produced under the authority of and in accordance with R.S. 40:1046.

(5) "Physician" has the meaning ascribed in R.S. 37:1262.

1 §1168.3. Data system; components; reporting; design in collaboration with medical
 2 schools; public records exception

3 A. The board may create and maintain an electronic system for the collection
 4 and analysis of clinical information associated with the use of medical marijuana by
 5 patients. The system shall include, at minimum, the following components:

6 (1)(a) A component for the collection of data concerning adverse events
 7 experienced by patients which are associated with the use of medical marijuana.

8 (b) The board shall design and administer the data system such that any of
 9 the following persons may report an adverse event:

10 (i) The patient.

11 (ii) A family member of the patient.

12 (iii) A physician who prescribes or recommends medical marijuana to a
 13 patient.

14 (iv) Any physician who treats a patient other than a physician who prescribes
 15 or recommends medical marijuana to the patient.

16 (2)(a) A component for the collection of data concerning health outcomes
 17 other than adverse events experienced by patients that are associated with the use of
 18 medical marijuana.

19 (b) The board shall design and administer the data system such that reporting
 20 of health outcomes is limited to physicians exclusively.

21 B. The board shall collaborate with the following institutions in designing
 22 and implementing the data system:

23 (1) The medical school of the Louisiana State University Health Sciences
 24 Center at New Orleans.

25 (2) The medical school of the Louisiana State University Health Sciences
 26 Center at Shreveport.

27 (3) The Tulane University School of Medicine.

28 (4) The Pennington Biomedical Research Center.

29 (5) The College of Nursing and Allied Health at Southern University and
 30 Agricultural and Mechanical College.

1 (6) The Xavier University of Louisiana College of Pharmacy.

2 C. Except in cases of disclosure of data authorized by R.S. 40:1168.4(B), all
3 data in the data system shall be confidential and shall not be available for subpoena,
4 nor shall such information be disclosed, discoverable, or compelled to be produced
5 in any civil, criminal, administrative, or other proceeding. The data maintained in
6 the data system shall not be subject to any public records request nor shall any such
7 data be considered as a public record pursuant to R.S. 44:1 et seq.

8 §1168.4. Protection of health information; limitations on data use

9 A. The board shall maintain the data system in a secure environment which
10 complies, at minimum, with all applicable federal laws and regulations providing for
11 the protection of health information.

12 B.(1) The board may authorize and facilitate access to data in the system to
13 an outside party only if that party seeks the data for use in a bona fide medical
14 research effort which has been authorized by the institutional review board of the
15 organization conducting the research.

16 (2) The board shall have exclusive authority to determine whether an activity
17 qualifies as a bona fide medical research effort in accordance with Paragraph (1) of
18 this Subsection.

19 (3) Any disclosure of data in the system shall be subject to the approval of
20 the board.

21 §1168.5. Funding sources authorized for data system

22 The board is hereby authorized to receive and expend all funds as may be
23 necessary to implement and maintain the data system. Such funds may include,
24 without limitation, funds appropriated by the legislature, including any appropriation
25 of federal funds; funding provided by contract or other agreement with a
26 governmental entity; and any public or private donations, gifts, or grants from
27 governmental sources, individuals, corporations, nonprofit organizations, or other
28 business entities.

1
2
3
4

(6) Physicians shall report adverse events and health outcomes associated with a patient's use of medical marijuana to the data system provided for in R.S. 40:1168.1 et seq.

* * *

SPEAKER OF THE HOUSE OF REPRESENTATIVES

PRESIDENT OF THE SENATE

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____